SCHEMBL4331572

SCHEMBL4331572

CSc1ccc(C(=O)O)nc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 12/20 0.53
P4HA1 P13674 1/20 0.53
MIF P14174 1/20 0.53
KDM4E B2RXH2 4/20 0.52
ALDH1A1 P00352 2/20 0.52
L3MBTL1 Q9Y468 4/20 0.49
MAPK1 P28482 1/20 0.49
KMT2A Q03164 2/20 0.46
HIF1A Q16665 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
THPO P40225 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901448 0.85 P4HTM (0.37) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL5371986 0.84 ALDH1A1 (0.44) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL3608608 0.79 ADORA3 (0.40) P4HTMKDM4EALDH1A1L3MBTL1KMT2A
SCHEMBL29694969 0.79 MAPK1 (0.61) KDM4EALDH1A1L3MBTL1MAPK1KMT2A
SCHEMBL5211462 0.79 MAPK1 (0.61) KDM4EALDH1A1L3MBTL1MAPK1KMT2A
SCHEMBL28005591 0.79 P4HTM (0.48) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL1403482 0.79 KDM4E (0.50) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL3613594 0.77 PCSK9 (0.36) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL11265059 0.77 KDM4E (0.51) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL2656296 0.75 CYP1A2 (0.49) KDM4EALDH1A1MAPK1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3327013-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2019-04-24 EP disclosed
EP-3327013-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS Celgene Corporation (US) 2018-05-30 EP disclosed
EP-3061758-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2018-01-31 EP disclosed
US-9801868-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2017-10-31 US disclosed
US-20160346264-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2016-12-01 US disclosed
US-9447070-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2016-09-20 US disclosed
EP-3061758-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS Celgene Corporation (US) 2016-08-31 EP disclosed
EP-2749559-B1 5-substituted isoindoline compounds CELGENE CORP (US) 2016-04-27 EP disclosed
EP-2291365-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2015-03-11 EP disclosed
US-20150005303-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2015-01-01 US disclosed
US-8877780-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2014-11-04 US disclosed
EP-2749559-A1 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2014-07-02 EP disclosed
WO-2009145899-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2009-12-03 WO disclosed
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2009-06-04 US disclosed
EP-0053789-B1 2-PYRIDINECARBOXAMIDE DERIVATIVE, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION, USEFUL AS AN ANTI-ALLERGIC AGENT Tanabe Seiyaku Co., Ltd. (JP) 1985-03-27 EP disclosed
US-4404214-A 2-Pyridinecarboxamide derivatives compositions containing same and method of using same TANABE SEIYAKU CO., LTD. (JP) 1983-09-13 US disclosed
EP-0053789-A1 2-Pyridinecarboxamide derivative, process for preparing same and pharmaceutical composition, useful as an anti-allergic agent Tanabe Seiyaku Co., Ltd. (JP) 1982-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160346264-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 P4HTM 2013/4885P4HA1 2304/4885MIF 681/4885
US-20150005303-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 P4HTM 2013/4885P4HA1 2304/4885MIF 681/4885
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 P4HTM 2013/4885P4HA1 2304/4885MIF 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.